BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tallon C, Hollinger KR, Pal A, Bell BJ, Rais R, Tsukamoto T, Witwer KW, Haughey NJ, Slusher BS. Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. Drug Discov Today 2021;26:1656-68. [PMID: 33798648 DOI: 10.1016/j.drudis.2021.03.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Matsuzaka Y, Yashiro R. Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine. Int J Mol Sci 2022;23:6480. [PMID: 35742923 DOI: 10.3390/ijms23126480] [Reference Citation Analysis]
2 Tallon C, Picciolini S, Yoo SW, Thomas AG, Pal A, Alt J, Carlomagno C, Gualerzi A, Rais R, Haughey NJ, Bedoni M, Slusher BS. Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury. Biochem Pharmacol 2021;194:114796. [PMID: 34678224 DOI: 10.1016/j.bcp.2021.114796] [Reference Citation Analysis]
3 Pal A, Gori S, Yoo SW, Thomas AG, Wu Y, Friedman J, Tenora L, Bhasin H, Alt J, Haughey N, Slusher BS, Rais R. Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP. J Med Chem 2022. [PMID: 35930706 DOI: 10.1021/acs.jmedchem.2c00562] [Reference Citation Analysis]
4 Huang Y. Extracellular Vesicles and Ciliogenesis as Novel Targets to Stop Opioid Tolerance. Biol Psychiatry 2021;90:e39-40. [PMID: 34556206 DOI: 10.1016/j.biopsych.2021.08.007] [Reference Citation Analysis]
5 Zhu X, Hollinger KR, Huang Y, Borjabad A, Kim B, Arab T, Thomas AG, Moniruzzaman M, Lovell L, Turchinovich A, Witwer KW, Volsky DJ, Haughey NJ, Slusher BS. Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV. Neurobiology of Disease 2022;169:105734. [DOI: 10.1016/j.nbd.2022.105734] [Reference Citation Analysis]